These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 30137686)
61. Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Tanaka Y; Yoshida K; Sanada Y; Osada S; Yamaguchi K; Takahashi T Cancer Chemother Pharmacol; 2010 Nov; 66(6):1159-65. PubMed ID: 20878160 [TBL] [Abstract][Full Text] [Related]
62. Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study. Choi N; Park SD; Lynch T; Wright C; Ancukiewicz M; Wain J; Donahue D; Mathisen D Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):111-22. PubMed ID: 15337546 [TBL] [Abstract][Full Text] [Related]
63. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen. Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R Tumori; 2010; 96(1):48-53. PubMed ID: 20437857 [TBL] [Abstract][Full Text] [Related]
64. Additional Effects of Docetaxel on Neoadjuvant Radiotherapy With Cisplatin/5-Fluorouracil for Esophageal Squamous Cell Carcinoma. Sasaki K; Tsuruda Y; Shimonosono M; Noda M; Uchikado Y; Arigami T; Matsushita D; Mori S; Nakajo A; Kurahara H; Ohtsuka T Anticancer Res; 2022 Aug; 42(8):3905-3911. PubMed ID: 35896244 [TBL] [Abstract][Full Text] [Related]
65. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166 [TBL] [Abstract][Full Text] [Related]
66. Randomized Phase II Study to Comparing Docetaxel/Nedaplatin versus Docetaxel for 5-Fluorouracil/Cisplatin Resistant Esophageal Squamous Cell Carcinoma. Yajima S; Suzuki T; Nanami T; Oshima Y; Kikuchi Y; Funahashi K; Shimada H Ann Thorac Cardiovasc Surg; 2021 Aug; 27(4):219-224. PubMed ID: 33408308 [TBL] [Abstract][Full Text] [Related]
67. Multicenter phase I/II study of docetaxel, cisplatin and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Yamasaki M; Miyata H; Tanaka K; Shiraishi O; Motoori M; Peng YF; Yasuda T; Yano M; Shiozaki H; Mori M; Doki Y Oncology; 2011; 80(5-6):307-13. PubMed ID: 21778771 [TBL] [Abstract][Full Text] [Related]
68. Docetaxel and cisplatin concurrent with radiotherapy versus 5-fluorouracil and cisplatin concurrent with radiotherapy in treatment for locally advanced oesophageal squamous cell carcinoma: a randomized clinical study. Zhao T; Chen H; Zhang T Med Oncol; 2012 Dec; 29(5):3017-23. PubMed ID: 22476809 [TBL] [Abstract][Full Text] [Related]
69. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma. Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603 [TBL] [Abstract][Full Text] [Related]
70. [Safety and Efficacy of Neoadjuvant Chemotherapy(UDON: 5-FU, Docetaxel, and Nedaplatin)for Esophageal Cancer]. Konishi T; Komatsu S; Takeda R; Kanazawa H; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y Gan To Kagaku Ryoho; 2023 Dec; 50(13):1381-1383. PubMed ID: 38303281 [TBL] [Abstract][Full Text] [Related]
71. Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial. Meluch AA; Greco FA; Gray JR; Thomas M; Sutton VM; Davis JL; Kalman LA; Shaffer DW; Yost K; Rinaldi DA; Hainsworth JD Cancer J; 2003; 9(4):251-60. PubMed ID: 12967135 [TBL] [Abstract][Full Text] [Related]
72. Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Ruhstaller T; Pless M; Dietrich D; Kranzbuehler H; von Moos R; Moosmann P; Montemurro M; Schneider PM; Rauch D; Gautschi O; Mingrone W; Widmer L; Inauen R; Brauchli P; Hess V J Clin Oncol; 2011 Feb; 29(6):626-31. PubMed ID: 21205757 [TBL] [Abstract][Full Text] [Related]
73. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Al-Batran SE; Hofheinz RD; Pauligk C; Kopp HG; Haag GM; Luley KB; Meiler J; Homann N; Lorenzen S; Schmalenberg H; Probst S; Koenigsmann M; Egger M; Prasnikar N; Caca K; Trojan J; Martens UM; Block A; Fischbach W; Mahlberg R; Clemens M; Illerhaus G; Zirlik K; Behringer DM; Schmiegel W; Pohl M; Heike M; Ronellenfitsch U; Schuler M; Bechstein WO; Königsrainer A; Gaiser T; Schirmacher P; Hozaeel W; Reichart A; Goetze TO; Sievert M; Jäger E; Mönig S; Tannapfel A Lancet Oncol; 2016 Dec; 17(12):1697-1708. PubMed ID: 27776843 [TBL] [Abstract][Full Text] [Related]
74. Effect of Time to Minimally Invasive Esophagectomy After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Loc NVV; Vuong NL; Trung LV; Trung TT J Gastrointest Cancer; 2023 Dec; 54(4):1240-1251. PubMed ID: 36723785 [TBL] [Abstract][Full Text] [Related]
75. [A case of the oldest old patient with advanced esophageal cancer responding completely to the combination chemotherapy of docetaxel/5-fluorouracil/nedaplatin with radiation]. Matsutani T; Sasajima K; Maruyama H; Suzuki S; Miyamoto M; Yokoyama T; Yanagi K; Matsushita A; Matsuda A; Tajiri T Nihon Shokakibyo Gakkai Zasshi; 2009 Jul; 106(7):1026-30. PubMed ID: 19578310 [TBL] [Abstract][Full Text] [Related]
76. Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouracil-oxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase 2 trial. Messager M; Mirabel X; Tresch E; Paumier A; Vendrely V; Dahan L; Glehen O; Vasseur F; Lacornerie T; Piessen G; El Hajbi F; Robb WB; Clisant S; Kramar A; Mariette C; Adenis A BMC Cancer; 2016 May; 16():318. PubMed ID: 27194176 [TBL] [Abstract][Full Text] [Related]
77. Weekly docetaxel and gemcitabine in previously treated metastatic esophageal squamous cell carcinoma. Lee MY; Jung KS; Kim HS; Lee JY; Lim SH; Kim M; Jung HA; Kim SM; Sun JM; Ahn MJ; Lee J; Park SH; Yi SY; Hwang IG; Lee SC; Ahn HK; Lim DH; Lee SI; Park KW World J Gastroenterol; 2015 Apr; 21(14):4268-74. PubMed ID: 25892878 [TBL] [Abstract][Full Text] [Related]
78. Preoperative low-dose weekly cisplatin and continuous infusion fluorouracil plus hyperfractionated radiotherapy in stage II-III esophageal carcinoma. Caro M; Font A; Comas S; Viciano M; Remon J; Céliz P; Robles J; Musulén E; Sendrós MJ; Mesalles E; Jiménez JA; Boix J; Arellano A; Fernández-Llamazares J Clin Transl Oncol; 2016 Nov; 18(11):1106-1113. PubMed ID: 26856597 [TBL] [Abstract][Full Text] [Related]
79. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Al-Batran SE; Hartmann JT; Hofheinz R; Homann N; Rethwisch V; Probst S; Stoehlmacher J; Clemens MR; Mahlberg R; Fritz M; Seipelt G; Sievert M; Pauligk C; Atmaca A; Jäger E Ann Oncol; 2008 Nov; 19(11):1882-7. PubMed ID: 18669868 [TBL] [Abstract][Full Text] [Related]
80. [Phase II clinical trial of home-produced Nedaplatin in treating advanced esophageal carcinoma]. Xu RH; Shi YX; Guan ZZ; Jiang WQ; Huang H; Ma ZY; Wang JH; Hu XH; Xie WM; Li XG; Liu YL; Pan LX; Dai AD; Zhuang W; Zhang C Ai Zheng; 2006 Dec; 25(12):1565-8. PubMed ID: 17166388 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]